ArticleJournal of thrombosis and thrombolysis2026
Efficacy and safety of low-dose tirofiban plus dual antiplatelet therapy in acute cerebral infarction beyond the thrombolysis window: a non-randomized trial with preliminary findings.
Article in Journal of thrombosis and thrombolysis, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optimal antithrombotic strategies for patients with acute cerebral infarction beyond the thrombolysis window (6-24 h) without large or medium-sized vessel occlusion remain uncertain. This study evaluated the efficacy and safety of low-dose tirofiban combined with dual antiplatelet therapy (DAPT) in this population. This single-center, retrospective, non-randomized study enrolled 229 patients. The tirofiban group (n = 114) received low-dose tirofiban (0.1 µg/kg/min for 24 h) followed by DAPT, while the control group (n = 115) received DAPT alone. Inverse probability of treatment weighting (IPTW) balanced baseline covariates. The primary outcome was favorable functional outcome (modified Rankin Scale score 0-2) at 90 days. Secondary outcomes included excellent functional outcome (mRS 0-1 at 90 days), NIHSS improvement (≥ 3 points from baseline to 72 h) and early neurological deterioration (END). Safety outcomes included bleeding and symptomatic intracranial hemorrhage (sICH). Sensitivity analyses and E-values were calculated. After IPTW, all baseline covariates achieved excellent balance (all SMDs < 0.1). The primary outcome showed no significant difference between groups (OR = 0.41, 95% CI: 0.12-1.38, P = 0.151). However, tirofiban was associated with significantly higher odds of excellent functional outcome (mRS 0-1) (OR = 2.01, 95% CI: 1.07-3.77, P = 0.031) and NIHSS improvement (OR = 2.57, 95% CI: 1.42-4.66, P = 0.002). No significant differences were observed in END, bleeding, or sICH. Sensitivity analyses confirmed the robustness of tirofiban's benefit for both outcomes, with E-values of 4.58 and 3.43, respectively. Low-dose tirofiban combined with DAPT significantly improved early neurological recovery and excellent functional outcome without increasing bleeding or sICH risk. Although the primary outcome did not reach statistical significance, consistent sensitivity analyses support the clinical value of tirofiban. Larger randomized controlled trials are warranted.
Indexed as
Identifiers
42629531What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.